Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124484458 | 12448445 | 8 | F | 20160526 | 20160830 | 20160608 | 20160909 | EXP | GB-PFIZER INC-2016291353 | PFIZER | 73.00 | YR | M | Y | 65.00000 | KG | 20160909 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124484458 | 12448445 | 1 | PS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | 135 MG, EVERY 3 WEEKS | Y | 305416 | 22234 | 135 | MG | SOLUTION FOR INJECTION | Q3W | ||||
| 124484458 | 12448445 | 2 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | UNK | Y | 305417 | 22234 | SOLUTION FOR INJECTION | |||||||
| 124484458 | 12448445 | 3 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | UNK | Y | 306134 | 22234 | SOLUTION FOR INJECTION | |||||||
| 124484458 | 12448445 | 4 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | UNK | Y | 306135 | 22234 | SOLUTION FOR INJECTION | |||||||
| 124484458 | 12448445 | 5 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | UNK | Y | 3061 | 22234 | SOLUTION FOR INJECTION | |||||||
| 124484458 | 12448445 | 6 | SS | DOCETAXEL. | DOCETAXEL | 1 | Intravenous (not otherwise specified) | 100 MG, UNK | Y | 22234 | 100 | MG | SOLUTION FOR INJECTION | ||||||
| 124484458 | 12448445 | 7 | C | QUININE SULPHATE | QUININE SULFATE | 1 | Oral | 300 MG, 1X/DAY | 0 | 300 | MG | QD | |||||||
| 124484458 | 12448445 | 8 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 30 MG, 1X/DAY | 0 | 30 | MG | QD | |||||||
| 124484458 | 12448445 | 9 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | QD | |||||||
| 124484458 | 12448445 | 10 | C | MOVICOL | POLYETHYLENE GLYCOL 3350POTASSIUM CHLORIDESODIUM BICARBONATESODIUM CHLORIDE | 1 | Oral | 13.8 MG, UNK | 0 | 13.8 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124484458 | 12448445 | 1 | Non-small cell lung cancer |
| 124484458 | 12448445 | 7 | Muscle spasms |
| 124484458 | 12448445 | 8 | Peptic ulcer |
| 124484458 | 12448445 | 9 | Prophylaxis |
| 124484458 | 12448445 | 10 | Constipation |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124484458 | 12448445 | HO |
| 124484458 | 12448445 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124484458 | 12448445 | Neutropenia | |
| 124484458 | 12448445 | Septic shock |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124484458 | 12448445 | 1 | 20160330 | 0 | ||
| 124484458 | 12448445 | 4 | 20160518 | 0 | ||
| 124484458 | 12448445 | 6 | 20160518 | 0 | ||
| 124484458 | 12448445 | 7 | 2016 | 0 | ||
| 124484458 | 12448445 | 8 | 2016 | 0 | ||
| 124484458 | 12448445 | 9 | 2016 | 0 | ||
| 124484458 | 12448445 | 10 | 2016 | 0 |